Back to today’s briefing

Story perspectives

Blackstone Life Sciences VI Raises $6.3 Billion for Drug Development

3/31/2026

50 11 Full Breakdown

Summary

Story summary

Blackstone Life Sciences VI closed with $6.3 billion, the largest private life sciences fund and about 40% larger than its predecessor.
Launched in 2018, the fund focuses on late-stage drug development and has achieved 34 regulatory approvals for medicines and devices.
Nicholas Galakatos, head of Blackstone Life Sciences, said the fund has strong partnerships and committed $2 billion in new investments with an 86% Phase III asset approval rate.

1 of 1

Story summary

Blackstone Life Sciences VI closed with $6.3 billion, the largest private life sciences fund and about 40% larger than its predecessor.
Launched in 2018, the fund focuses on late-stage drug development and has achieved 34 regulatory approvals for medicines and devices.
Nicholas Galakatos, head of Blackstone Life Sciences, said the fund has strong partnerships and committed $2 billion in new investments with an 86% Phase III asset approval rate.